Background: Cesarean section (C-section) is one of the most commonly performed surgery in modern obstetrics. Due to this the worldwide continuous rise in the incidence of cesarean sections, the number of women with postpartum infection is expected to increase. Postpartum infections are a major cause of prolonged hospital stay and increase burden to our health care system. The objective of this study was to determine the incidence and risk factor for the of Surgical site infections (SSI). Methods: A Retrospective analytical study was conducted at Smt. Kashibai Navale medical college and general hospital, Pune. 1269 Patients undergoing LSCS from January 2017 to December 2017 were included after satisfying inclusion and exclusion criteria were included in the study. Results: Out of 1269 LSCS patient, 56(4.4%) of them had SSI, which represents the incidence rate of SSI post LSCS in our study. Anemia and previous caesarean were important risk factor for SSI in our study. Prolonged surgery was found to be statistically significant etiological factor in the study. MRSA (37.5%) was the commonest pathogen to produce SSI in our series, followed by sterile culture in 21% cases. Conclusion: Surgical site infection (SSI) following cesarean delivery was noted in 4.4% patients and it is a major cause of burden of disease both for the patients and the healthcare system in terms of the morbidity, and economic costs. Multidisciplinary team approach has proven effective for decreasing the incidence to minimal level. Reduction in incidence of SSI may be achieved by use of peri operative antibiotics, correction of anemia, use of proper surgical techniques and minimizing the duration of surgery. Pre-operative and post LSCS antibiotic policy should depend on types of bacteria isolated by culture and there resistance mechanism. This may effectively contribute in decreasing SSI after LSCS.
Background: The post-partum period is challenging enough for most new mothers. Recovering from birth, learning to parent, and taking care of her child requires lot of energy. Having anemia in postpartum period can make this process much more difficult. According to WHO, in India incidence of anemia in postnatal mother is around 58% and according to ICMR prevalence of anemia in Tamil Nadu population 76% during pregnancy. The objective of this study was to compare the efficacy of intravenous iron supplementation with Iron sucrose to the oral supplementation with ferrous ascorbate in management of patient with post-partum anemia. To study the safety and side effects of these two preparations.Methods: This was a prospective study conducted on 100 post-partum anemic women in KG Hospital in Coimbatore, October 2012 to November 2013 with hemoglobin less than 10g/dl but more than 6g/dl within 24-48 hours of delivery ,after satisfying inclusion and exclusion criteria were included in the study.Results: Mean hemoglobin of oral group was 8.49±0.75 and mean hemoglobin of IV group was 8.43±0.76; 24 hours after delivery. After treatment, that is after 4 weeks mean hemoglobin of oral group was 10.38±0.79 and mean hemoglobin of IV group was 11.20±0.71.on comparing both groups, the increase in hemoglobin in the IV groups was significant. Reticulocyte count and other parameters increased significantly after four wks of starting therapy in IV group compare to the oral group. No major side effects or anaphylactic reactions were noted during study period.Conclusions: Intravenous iron sucrose complex is safe, convenient and effective in postpartum anemic women as compared with the oral ferrous ascorbate. Intravenous iron sucrose have shorter treatment periods, increased likelihood of compliance, a lack of gastrointestinal side effects, and rapid replenishment of iron stores, making them superior to oral ferrous ascorbate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.